InflaRx N.V.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.9
- Today's High:
- $4.015
- Open Price:
- $4
- 52W Low:
- $1.57
- 52W High:
- $7.25
- Prev. Close:
- $4
- Volume:
- 66108
Company Statistics
- Market Cap.:
- $235.53 million
- Book Value:
- 2.117
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.79%
- Return on Equity TTM:
- -31.07%
Company Profile
InflaRx N.V. had its IPO on 2017-11-08 under the ticker symbol IFRX.
The company operates in the Healthcare sector and Biotechnology industry. InflaRx N.V. has a staff strength of 44 employees.
Stock update
Shares of InflaRx N.V. opened at $4 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.9 - $4.02, and closed at $3.98.
This is a -0.5% slip from the previous day's closing price.
A total volume of 66,108 shares were traded at the close of the day’s session.
In the last one week, shares of InflaRx N.V. have slipped by -4.1%.
InflaRx N.V.'s Key Ratios
InflaRx N.V. has a market cap of $235.53 million, indicating a price to book ratio of 0.9727 and a price to sales ratio of 0.
In the last 12-months InflaRx N.V.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-54931944. The EBITDA ratio measures InflaRx N.V.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, InflaRx N.V.’s operating margin was 0% while its return on assets stood at -27.79% with a return of equity of -31.07%.
In Q2, InflaRx N.V.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
InflaRx N.V.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.75 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into InflaRx N.V.’s profitability.
InflaRx N.V. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.0439. Its price to sales ratio in the trailing 12-months stood at 0.
InflaRx N.V. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $132.96 million
- Total Liabilities
- $7.47 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $18627
- Dividend Payout Ratio
- 0%
InflaRx N.V. ended 2024 with $132.96 million in total assets and $0 in total liabilities. Its intangible assets were valued at $132.96 million while shareholder equity stood at $124.65 million.
InflaRx N.V. ended 2024 with $0 in deferred long-term liabilities, $7.47 million in other current liabilities, 7065993.00 in common stock, $-262746253.00 in retained earnings and $0 in goodwill. Its cash balance stood at $19.52 million and cash and short-term investments were $102.31 million. The company’s total short-term debt was $356,099 while long-term debt stood at $0.
InflaRx N.V.’s total current assets stands at $112.22 million while long-term investments were $18.95 million and short-term investments were $82.79 million. Its net receivables were $2.93 million compared to accounts payable of $5.20 million and inventory worth $578705.00.
In 2024, InflaRx N.V.'s operating cash flow was $0 while its capital expenditure stood at $18627.
Comparatively, InflaRx N.V. paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.98
- 52-Week High
- $7.25
- 52-Week Low
- $1.57
- Analyst Target Price
- $10.76
InflaRx N.V. stock is currently trading at $3.98 per share. It touched a 52-week high of $7.25 and a 52-week low of $7.25. Analysts tracking the stock have a 12-month average target price of $10.76.
Its 50-day moving average was $3.94 and 200-day moving average was $3.37 The short ratio stood at 1.1 indicating a short percent outstanding of 0%.
Around 1309.9% of the company’s stock are held by insiders while 1929% are held by institutions.
Frequently Asked Questions About InflaRx N.V.
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.